Home > Riviste > Minerva Gastroenterology > Fascicoli precedenti > Articles online first > Minerva Gastroenterology 2022 May 05



Opzioni di pubblicazione
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo


Original Article   

Minerva Gastroenterology 2022 May 05

DOI: 10.23736/S2724-5985.22.03173-4


lingua: Inglese

Safety and efficacy of Oryza sativa topical treatment in subjects with hemorrhoidal disease: a randomized, double blind, clinical trial

Alessandro STURIALE 1 , Lisa FRALLEONE 1, Danilo CAFARO 2, Gaetano GALLO 3, Luigi BRUSCIANO 4, Felipe CELEDON PORZIO 5, Sreedhara VENKATARATNAIAH SETTY 6, Gabriele NALDINI 1

1 Proctology and Pelvic Floor Clinical Centre, Cisanello University Hospital, Pisa, Italy; 2 Proctology surgery, Tropea Hospital, Vibo Valentia, Italy; 3 Department of Medical and Surgical Sciences, University of Catanzaro, Catanzaro, Italy; 4 Division of General, Oncologic, Mininvasive and Bariatric Surgery, University of Campania Luigi Vanvitelli, Naples, Italy; 5 Cirugia Coloproctologica, Hospital de la Fuerza Aerea de Chile, Santiago de Chile, Chile; 6 SPARSH Hospital, Bangalore, Karnataka, India


BACKGROUND: Hemorrhoidal disease (HD) is one of the most common anorectal benign disorder affecting millions of people around the world. Grade I-II HD are generally treated with a conservative approach with topical products such as creams and ointments considered a safe and effective option to treat mild symptoms. The aim of the present study is to assess the safety and efficacy of a topical medical device (Lenoid™) in patients affected by symptomatic HD.
METHODS: This study is a randomized, double blind, placebo-controlled, 2-weeks clinical trial. Patients affected by I-II grade symptomatic HD were enrolled in the study and then randomly assigned to Lenoid™ Arm (LA) or Placebo Arm (PA), respectively. Patients were evaluated before and after intervention through clinical examination and disease-specific questionnaires assessing symptoms such as pain, tenesmus, pruritus and anal discharge.
RESULTS: A total of 68 patients were screened and 60 (30 in each group) were enrolled into the study. All patients belonging to LA showed a statistically significant improvement of each symptom after 7 and 14 days of treatment when compared to PA (p < 0.001). Furthermore, subjective improvement of change in overall assessment of disease was observed in the LA but not in the PA. No serious adverse events were recorded.
CONCLUSIONS: The tested product (Lenoid™) was found safe and effective in improving clinical signs and symptoms in patients with grade I-II HD.

KEY WORDS: Hemorrhoids; Oryza sativa; topical treatment

inizio pagina